Mitsubishi Chemical Group (4188) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
31 Jul, 2026Executive summary
First quarter FY2026 saw strong performance across all major segments, especially in Specialty Materials and Industrial Gases, despite challenging conditions from Middle East instability and soaring naphtha prices.
Core operating income rose by ¥57.5 billion year-on-year to ¥114.1 billion, with net income attributable to owners up ¥38.1 billion to ¥57.7 billion, driven by robust semiconductor-related demand, pricing strategies, and inventory valuation gains.
Inventory valuation gains and temporary demand increases, particularly from customer stockpiling, contributed significantly to results.
Financial highlights
Sales revenue for Q1 FY2026 reached ¥1,004.2 billion, up 14% year-on-year, with core operating income at ¥114.1 billion (+101.7% YoY) and net income attributable to owners at ¥57.7 billion (+194% YoY).
Operating income was ¥118.4 billion; income before taxes ¥111.8 billion.
Basic EPS for Q1: ¥42.47, up from ¥13.96 a year earlier.
Free cash flow for Q1 was ¥8.8 billion.
Special items contributed a positive ¥4.3 billion, including a ¥12.8 billion gain on asset sales.
Outlook and guidance
First-half forecasts for core operating income and net income were revised upward to ¥194.0 billion and ¥86.0 billion, respectively.
Full-year forecasts remain unchanged due to raw material price uncertainties.
Dividend forecast unchanged at ¥32 per share annually.
Q2 expected to see a reactionary decline in volumes and profits as inventory valuation gains diminish and customer stockpiling normalizes.
Latest events from Mitsubishi Chemical Group
- Aggressive green transformation and disciplined growth target JPY 900B COI by 2035.4188
Investor update - Specialty materials outperform as disciplined strategy and investments drive growth and transformation.4188
Investor Day 2025 - FY26 strategy targets growth in specialty materials, semiconductors, and composites, driven by reforms and investments.4188
Investor presentation - Profits fell on restructuring and impairments, but FY2026 rebound is forecast, led by Specialty Materials.4188
Q4 2026 - Net income surged on asset sales, but profit guidance was cut due to restructuring losses.4188
Q3 2026 - Sales and core operating income surged, but net income fell; major structural reforms underway.4188
Q1 2025 - Core operating income surged, but net income dropped on restructuring and special items.4188
Q2 2025 - Core operating income up 43%, net income down 62%, with major portfolio reforms and Pharma divestiture.4188
Q4 2025 - Revenue and core operating income rose, but net income fell on special losses; portfolio reforms ongoing.4188
Q3 2025